Philip J. Jewsbury
AstraZeneca (United Kingdom)(GB)
Publications by Year
Research Areas
Cancer-related Molecular Pathways, Advanced Chemical Physics Studies, Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Microtubule and mitosis dynamics
Most-Cited Works
- → A review of protein-small molecule docking methods(2002)643 cited
- → Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent(2018)321 cited
- → Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo(2016)215 cited
- → Identification of Novel Purine and Pyrimidine Cyclin-Dependent Kinase Inhibitors with Distinct Molecular Interactions and Tumor Cell Growth Inhibition Profiles(2000)215 cited
- → Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity(2013)214 cited
- → Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor(2002)212 cited
- → N2-Substituted O6-Cyclohexylmethylguanine Derivatives: Potent Inhibitors of Cyclin-Dependent Kinases 1 and 2(2004)122 cited
- → Imidazo[1,2-a]pyridines: A potent and selective class of cyclin-Dependent kinase inhibitors identified through structure-Based hybridisation(2003)114 cited
- → Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial(2024)108 cited
- → FDS: Flexible ligand and receptor docking with a continuum solvent model and soft‐core energy function(2003)92 cited